Form 4: Regeneron Director George L. Sing Reports Stock Transactions
SEC Form 4 Filing
Director George L. Sing reports acquisition and disposal of Regeneron Pharmaceuticals stock and stock options on December 31, 2024, and January 2, 2025.
Summary
- George L. Sing, a director of Regeneron Pharmaceuticals, reported transactions involving the company's stock.
- On December 31, 2024, Sing exercised stock options to acquire 3,338 shares at a price of $413.33 and disposed of 1,948 shares at $708.19.
- On January 2, 2025, Sing acquired 166 shares of restricted stock units.
- Following these transactions, Sing directly owns 27,828 shares of common stock.
- Sing also indirectly owns shares through his spouse and trusts for his son.
- Additionally, Sing acquired 1,958 non-qualified stock options on January 2, 2025, exercisable starting January 2, 2025, at a price of $719.37, expiring on January 2, 2035.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the trading activities of company directors.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The information disclosed is similar to that of other pharmaceutical company directors reporting their stock transactions.
- The filing adheres to SEC regulations and reporting requirements.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider trading activity.
- It can influence investor sentiment depending on the nature and volume of transactions.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Exercise of stock options and disposal of shares. |
| 01/02/2025 | Acquisition of restricted stock units and non-qualified stock options. |
| 01/03/2025 | Date of Form 4 signature. |
| 01/02/2035 | Expiration date of non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.